Program
Rabeprazole
Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.
Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 210 open or running | phase 3since Sep 12, 2005 | Aug 19, 2005 | none ahead |
| Johnson & Johnson | 150 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Pfizer | 40 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
| GlaxoSmithKline | 30 open or running | phase 4since May 14, 2015 | Sep 26, 2013 | none ahead |
| Viatris | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Lomond Therapeutics | 20 open or running | phase 1since May 1, 2024 | May 1, 2024 | none ahead |
| Torrent Pharmaceuticals | 20 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Boehringer Ingelheim | 10 open or running | phase 1since May 16, 2022 | May 16, 2022 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 4since May 20, 2013 | May 20, 2013 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Jun 15, 2015 | Jun 15, 2015 | none ahead |
| neutec-ar-ge-san-ve-tic-a-s | 10 open or running | phase 4since Feb 10, 2016 | Feb 10, 2016 | none ahead |
| pricara-unit-of-ortho-mcneil-inc | 10 open or running | phase 4since Oct 7, 2005 | Oct 7, 2005 | none ahead |
| yungjin-pharm-co-ltd | 10 open or running | phase 1since Jan 7, 2021 | Jan 7, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical and pierre-fabre-laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 40 studies since Aug 19, 2005.
- Sep 26, 2013GlaxoSmithKline's first study: phase 1 study in NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT01954043 · 23 enrolled · United States, Australia, United Kingdom
- Nov 15, 2013Torrent Pharmaceuticals's first studies: 2 phase 1 studies in HealthyNew to Torrent PharmaceuticalsTorrent Pharmaceuticals · NCT01990586, NCT01990378
- Mar 24, 2014Phase 3 study in Gastroesophageal RefluxEisai · NCT02135107 · 517 enrolled · Japan
- Mar 24, 2014Pfizer's first study: phase 1 study in HealthyNew to PfizerPfizer · NCT02097329 · 27 enrolled · United States
- Dec 4, 2014Phase 1 study in HealthyPfizer · NCT02311946 · 60 enrolled · United States
- May 14, 20152 phase 4 studies in Gastrointestinal DiseasesGlaxoSmithKline · NCT02605395, NCT02446483
- Jun 15, 2015Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02477306 · 60 enrolled · Egypt
- Feb 10, 2016neutec-ar-ge-san-ve-tic-a-s's first study: phase 4 study in Gastroesophageal RefluxNew to neutec-ar-ge-san-ve-tic-a-sneutec-ar-ge-san-ve-tic-a-s · NCT02689999 · 12 enrolled · Turkey
- Jun 16, 2017Phase 1 study in Healthy VolunteerPfizer · NCT03220191 · 12 enrolled · United States
- Jan 7, 2021yungjin-pharm-co-ltd's first study: phase 1 study in Gastroesophageal RefluxNew to yungjin-pharm-co-ltdyungjin-pharm-co-ltd · NCT04703868 · 88 enrolled · Korea, Republic of
- May 16, 2022Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT05380947 · 13 enrolled · Germany
- Jul 1, 2022Phase 1 study in HealthyPfizer · NCT05446142 · 18 enrolled · United States
- May 1, 2024Lomond Therapeutics's first study: phase 1 study in AMLNew to Lomond TherapeuticsLomond Therapeutics · NCT06399315 · 112 enrolled · Australia
- Jan 16, 2025Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellLomond Therapeutics · NCT06787131 · 104 enrolled · Australia
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 56 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06787131Leukemia, Lymphocytic, Chronic, B-Cell · Australia | 1 | Completed | Lomond Therapeutics | Jul 4, 2025 | 104 |
| NCT06399315AML · Australia | 1 | Completed | Lomond Therapeutics | Jun 30, 2025 | 112 |
| NCT05446142Healthy · United States | 1 | Completed | Pfizer | Sep 30, 2022 | 18 |
| NCT05380947Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 13, 2022 | 13 |
| NCT04703868Gastroesophageal Reflux · Korea, Republic of | 1 | Completed | yungjin-pharm-co-ltd | Jun 1, 2021 | 88 |
| NCT03220191Healthy Volunteer · United States | 1 | Completed | Pfizer | Sep 3, 2017 | 12 |
| NCT02689999Gastroesophageal Reflux · Turkey | 4 | Completed | neutec-ar-ge-san-ve-tic-a-s | May 2017 | 12 |
| NCT02477306Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Mar 2014 | 60 |
| NCT02605395Gastrointestinal Diseases · Egypt | 4 | Completed | GlaxoSmithKline | Mar 30, 2014 | 70 |
| NCT02446483Gastrointestinal Diseases · Egypt | 4 | Completed | GlaxoSmithKline | Mar 26, 2014 | 60 |
| NCT02311946Healthy · United States | 1 | Completed | Pfizer | Apr 2015 | 60 |
| NCT02135107Gastroesophageal Reflux · Japan | 3 | Completed | Eisai | May 2016 | 517 |
| NCT02097329Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 27 |
| NCT01990586Healthy · India | 1 | Completed | Torrent Pharmaceuticals | Sep 2010 | |
| NCT01990378Healthy · India | 1 | Completed | Torrent Pharmaceuticals | Sep 2010 | |
| NCT01954043Neoplasms · United States, Australia, United Kingdom | 1 | Completed | GlaxoSmithKline | Feb 29, 2016 | 23 |
| NCT01860482Esophagitis, Peptic · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | May 2015 | 39 |
| NCT01398410Stomach Ulcer · Japan | 3 | Completed | Eisai | Dec 2013 | 405 |
| NCT01397448Stomach Ulcer · Japan | 3 | Completed | Eisai | Mar 2013 | 472 |
| NCT01241409Healthy | 1 | Completed | Johnson & Johnson | Dec 2010 | 78 |
| NCT01202071Healthy · Japan | 2 | Completed | Eisai | Dec 2010 | 24 |
| NCT01186497Healthy | 1 | Completed | Johnson & Johnson | Nov 2010 | 35 |
| NCT01153659Healthy · United States | 1 | Completed | Eisai | Aug 2010 | 90 |
| NCT01089543Dyspepsia · Japan | 2 | Completed | Eisai | Aug 2011 | 338 |
| NCT01101646Gastroesophageal Reflux · United States | 1 | Completed | Johnson & Johnson | Sep 2008 | 36 |
| NCT01085708Healthy | 1 | Completed | Eisai | May 2010 | 16 |
| NCT01085695Healthy | 1 | Completed | Eisai | May 2010 | 16 |
| NCT01008696Esophagitis, Peptic | 4 | Completed | Johnson & Johnson | Aug 2008 | 217 |
| NCT00992589Gastroesophageal Reflux · United States, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Nov 2011 | 344 |
| NCT00911534Gastroesophageal Reflux · United States | 3 | Completed | Eisai | Jul 2009 | 305 |
| NCT00855361Gastroesophageal Reflux · United States, Germany, Poland and more | 1 | Completed | Johnson & Johnson | Dec 2011 | 69 |
| NCT00839306Gastroesophageal Reflux · United States | 3 | Completed | Eisai | Aug 2009 | 240 |
| NCT00838526Gastroesophageal Reflux · United States | 3 | Completed | Eisai | Jul 31, 2009 | 240 |
| NCT00787891Gastroesophageal Reflux | 3 | Completed | Johnson & Johnson | Jan 2011 | 127 |
| NCT00770913Esophagitis, Peptic · Japan | 3 | Completed | Eisai | Nov 2009 | 337 |
| NCT00747695Gastroesophageal Reflux | 1 | Completed | Johnson & Johnson | 31 | |
| NCT00747526Gastroesophageal Reflux · United States, Belgium, Brazil and more | 1 | Completed | Johnson & Johnson | Feb 2012 | 51 |
| NCT00658775Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | Eisai | Sep 2009 | 1,069 |
| NCT00658632Gastroesophageal Reflux · United States | 3 | Completed | Eisai | Apr 2009 | 1,397 |
| NCT00658528Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | Eisai | Sep 2009 | 1,061 |
| NCT00649493Healthy · United States | 1 | Completed | Viatris | Jun 2003 | 72 |
| NCT00649194Healthy · United States | 1 | Completed | Viatris | Aug 2003 | 72 |
| NCT00648349Healthy · United States | 1 | Completed | Viatris | Jun 2003 | 72 |
| NCT00553449Gastroesophageal Reflux | 3 | Completed | Johnson & Johnson | 48 | |
| NCT00464308Gastroesophageal Reflux · Australia | 4 | Completed | Johnson & Johnson | May 2008 | 1,392 |
| NCT00378287Gastroesophageal Reflux | 1 | Completed | Johnson & Johnson | 37 | |
| NCT00236197Heartburn · United States | 3 | Completed | Eisai | Mar 2006 | 619 |
| NCT00236184Heartburn · United States | 3 | Completed | Eisai | Mar 2006 | 629 |
| NCT00237367Gastroesophageal Reflux | 4 | Completed | pricara-unit-of-ortho-mcneil-inc | 52 | |
| NCT00236392Gastroesophageal Reflux | 3 | Completed | Johnson & Johnson | 422 | |
| NCT00216489Gastroesophageal Reflux | 4 | Completed | Johnson & Johnson | 191 | |
| NCT00216450Helicobacter Infections | 4 | Completed | Johnson & Johnson | 80 | |
| NCT00165841Gastroesophageal Reflux · United States | 2 | Completed | Eisai | Dec 2005 | 200 |
| NCT00165672Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Eisai | Oct 2005 | 26 |
| NCT00165646Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Eisai | Oct 2005 | 288 |
| NCT00132496Gastroesophageal Reflux · United States | 2 | Completed | Eisai | May 2006 | 111 |
How it is read
Names in the registry
- “Rabeprazole”, 15 entries
- “rabeprazole”, 14 entries
- “rabeprazole sodium”, 10 entries
- “E3810”, 8 entries
- “Rabeprazole sodium”, 6 entries
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 25 studies
- Esophagitis, Peptic, 3 studies
- Gastrointestinal Diseases, 2 studies
- Stomach Ulcer, 2 studies
- Heartburn, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.